EuBiologics Future Growth
Future criteria checks 6/6
EuBiologics is forecast to grow earnings and revenue by 93.4% and 28.1% per annum respectively. EPS is expected to grow by 92.7% per annum. Return on equity is forecast to be 20.4% in 3 years.
Key information
93.4%
Earnings growth rate
92.7%
EPS growth rate
| Biotechs earnings growth | 43.7% |
| Revenue growth rate | 28.1% |
| Future return on equity | 20.4% |
| Analyst coverage | Low |
| Last updated | 06 Feb 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 128,000 | 34,000 | 35,000 | 44,000 | 1 |
| 12/31/2024 | 116,000 | 29,000 | 19,000 | 28,000 | 1 |
| 12/31/2023 | 69,366 | -13,879 | -17,205 | 26,452 | N/A |
| 9/30/2023 | 59,892 | -4,361 | -20,308 | 18,592 | N/A |
| 6/30/2023 | 61,222 | -1,010 | -29,004 | 11,117 | N/A |
| 3/31/2023 | 59,140 | -1,323 | -19,783 | 2,854 | N/A |
| 12/31/2022 | 55,467 | -1,099 | -18,486 | 6,440 | N/A |
| 9/30/2022 | 50,472 | 2,022 | -18,483 | 6,273 | N/A |
| 6/30/2022 | 48,534 | 3,808 | -18,634 | -688 | N/A |
| 3/31/2022 | 42,810 | -24,462 | -11,088 | 2,198 | N/A |
| 12/31/2021 | 39,385 | -27,574 | -16,761 | -7,602 | N/A |
| 12/31/2020 | 28,490 | -60,134 | -8,279 | 1,659 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A206650 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: A206650 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A206650 is expected to become profitable in the next 3 years.
Revenue vs Market: A206650's revenue (28.1% per year) is forecast to grow faster than the KR market (9.1% per year).
High Growth Revenue: A206650's revenue (28.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A206650's Return on Equity is forecast to be high in 3 years time (20.4%)